Anebulo Pharmaceuticals, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 57.27 | -100% | -9.07 | -100% |
| P/S |
|
0 | 33.44 | -100% |
|
|
| P/BV |
|
18.96 | 4.64 | 308.43% |
|
|
| P/FCF |
|
0 | 42.53 | -100% |
|
|
| Ev/Ebitda |
|
-8.6 | -17.68 | -51.37% |
|
|
| Ev/S |
|
0 | 22.59 | -100% |
|
|
| Ev/FCF |
|
-8.55 | 47.55 | -117.99% |
|
|
| E/P |
|
0 | 0.0182 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -14.2 | -100% | 0 | 0% |
| ROE |
|
-113.8 | 9.78 | -1263.31% |
|
|
| ROA |
|
-104.19 | 0.33 | -31669.02% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -26.41 | -100% |
|
|
| ROCE |
|
-217.93 | 14.55 | -1597.91% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | -3.87 | -100% | -0.2903 | -100% |
| Nеt Debt/Ebitda |
|
0.3844 | -4.24 | -109.06% |
|
|
| Debt/Ratio |
|
0 | 0.1853 | -100% |
|
|
| Debt/Equity |
|
0 | 1.61 | -100% |
|
|
| Debt/Net Income |
|
0 | 10.06 | -100% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5351 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2368 | -100% |
|
|
| Average dividend growth |
|
0 | 1.48 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4863 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.64 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5351 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 30.62 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
123.62 | -17.42 | -809.64% | ||
| Growth impulse Net Income in 5 years |
|
-72.93 | -52.26 | 39.55% | ||
| Growth impulse FCF in 5 years |
|
65.12 | -31.68 | -305.56% | ||
| Growth impulse EPS in 5 years |
|
-75.49 | -61.82 | 22.11% |
IP Score
3.2/10
